Aptevo Stock Rallies After Posting First Complete Remission In Early Acute Myeloid Leukemia Trial

Benzinga2021-11-23

Aptevo Therapeutics Inc has announced a clinical update for its Phase 1b Expansion trial evaluating APVO436 for acute myeloid leukemia (AML). A high-risk AML patient treated in Cohort 1 with a ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

WjsdSGTi
2021-11-24
WjsdSGTi
Cc
- WjsdSGTi:
  666
小白添祥
2021-11-24
小白添祥
like & comment please
phantom74
2021-11-24
phantom74
Like
- 小白添祥:
  like & comment please
Jay88
2021-11-24
Jay88
Ok
- phantom74:
  like
Sunny0809
2021-11-24
Sunny0809
Ok
- Jay88:
  ok
- TraderJo98:
  Ok
- T2C:
  Yes
3eb0d2e3
2021-11-24
3eb0d2e3
Ok
- Sunny0809:
  Ok
- 3eb0d2e3:
  ok

发表看法

201

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1156228294?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-11-23 23:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1156228294","market":"us","top_or_hot":-1,"title":"Aptevo Stock Rallies After Posting First Complete Remission In Early Acute Myeloid Leukemia Trial","media":"Benzinga","content":"<div>\n<p>Aptevo Therapeutics Inc has announced a clinical update for its Phase 1b Expansion trial evaluating APVO436 for acute myeloid leukemia (AML).\n\n\nA high-risk AML patient treated in Cohort 1 with a ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24248635/aptevo-stock-rallies-after-posting-first-complete-remission-in-early-acute-myeloid-leukemia-trial\">网页链接</a>\n\n</div>\n","source":"lsy1606299360108","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aptevo Stock Rallies After Posting First Complete Remission In Early Acute Myeloid Leukemia Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAptevo Stock Rallies After Posting First Complete Remission In Early Acute Myeloid Leukemia Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-23 23:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/11/24248635/aptevo-stock-rallies-after-posting-first-complete-remission-in-early-acute-myeloid-leukemia-trial><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Aptevo Therapeutics Inc has announced a clinical update for its Phase 1b Expansion trial evaluating APVO436 for acute myeloid leukemia (AML).\n\n\nA high-risk AML patient treated in Cohort 1 with a ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24248635/aptevo-stock-rallies-after-posting-first-complete-remission-in-early-acute-myeloid-leukemia-trial\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"APVO","symbol_name":"Aptevo Therapeutics Inc.","start_time":0,"source_url":"https://www.benzinga.com/general/biotech/21/11/24248635/aptevo-stock-rallies-after-posting-first-complete-remission-in-early-acute-myeloid-leukemia-trial","article_id":"1156228294","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1156228294","pubTimestamp":1637679908,"sourceInfo":{"source_id":"lsy1606299360108","name":"Benzinga"},"weMediaInfo":null,"summary":"Aptevo Therapeutics Inc has announced a clinical update for its Phase 1b Expansion trial evaluating ","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"APVO":"Aptevo Therapeutics Inc."},"translate_title":"Aptevo在早期急性髓细胞白血病试验中首次完全缓解后股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APVO":0.9},"content_text":"Aptevo Therapeutics Inc has announced a clinical update for its Phase 1b Expansion trial evaluating APVO436 for acute myeloid leukemia (AML).\n\n\nA high-risk AML patient treated in Cohort 1 with a combination of chemotherapy plus APVO436 achieved a complete remission (CR) after one cycle of therapy.\nThe chemotherapy regimen included the standard leukemia drugs Mitoxantrone, Etoposide, and Cytarabine.\nThe patient tolerated treatment without evidence of over toxicity.\nOverexpression of CD123 is the hallmark of many forms of leukemia. Aptevo's lead proprietary drug candidate, APVO436, is a bispecific CD3xCD123 ADAPTIR designed to redirect the patient's immune system to destroy leukemia cells expressing the target CD123 molecule on their surface.\nPrice Action: APVO shares are up 54.6% at $10.02 during the morning session on the last check Tuesday.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":875743870,"gmtCreate":1637706609231,"gmtModify":1637706609330,"author":{"id":"3576295596635298","authorId":"3576295596635298","name":"WjsdSGTi","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Cc","listText":"Cc","text":"Cc","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/875743870","repostId":1156228294,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6697285,"gmtCreate":1637706616062,"gmtModify":1637706616123,"authorId":3576295596635298,"author":{"id":3576295596635298,"authorId":3576295596635298,"name":"WjsdSGTi","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":875743870,"type":1,"supId":0,"prevId":0,"content":"666","text":"666","html":"666"}],"langContent":"CN"},{"id":875740718,"gmtCreate":1637706327762,"gmtModify":1637706328268,"author":{"id":"3571345352614779","authorId":"3571345352614779","name":"小白添祥","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"like &amp; comment please&nbsp;","listText":"like &amp; comment please&nbsp;","text":"like & comment please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875740718","repostId":1156228294,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":875757727,"gmtCreate":1637706123875,"gmtModify":1637706124146,"author":{"id":"3570342809089528","authorId":"3570342809089528","name":"phantom74","avatar":"https://static.tigerbbs.com/c87ef2af41b8696be86cceafb5b5723d","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/875757727","repostId":1156228294,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6697245,"gmtCreate":1637706333698,"gmtModify":1637706333801,"authorId":3571345352614779,"author":{"id":3571345352614779,"authorId":3571345352614779,"name":"小白添祥","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":875757727,"type":1,"supId":0,"prevId":0,"content":"like &amp; comment please ","text":"like &amp; comment please ","html":"like &amp; comment please "}],"langContent":"CN"},{"id":875757328,"gmtCreate":1637706010506,"gmtModify":1637706010619,"author":{"id":"4095547949553810","authorId":"4095547949553810","name":"Jay88","avatar":"https://static.tigerbbs.com/a2a8c91b2081859f5b526f88c16cc73a","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/875757328","repostId":1156228294,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6697223,"gmtCreate":1637706119909,"gmtModify":1637706120013,"authorId":3570342809089528,"author":{"id":3570342809089528,"authorId":3570342809089528,"name":"phantom74","avatar":"https://static.tigerbbs.com/c87ef2af41b8696be86cceafb5b5723d","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":875757328,"type":1,"supId":0,"prevId":0,"content":"<u>like</u>","text":"<u>like</u>","html":"<u>like</u>"}],"langContent":"CN"},{"id":875752330,"gmtCreate":1637705343556,"gmtModify":1637705343649,"author":{"id":"3581539047362830","authorId":"3581539047362830","name":"Sunny0809","avatar":"https://static.tigerbbs.com/3ffb7aab0292fd1f17dfb9f99bc5eb03","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/875752330","repostId":1156228294,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6697212,"gmtCreate":1637706019266,"gmtModify":1637706019348,"authorId":4095547949553810,"author":{"id":4095547949553810,"authorId":4095547949553810,"name":"Jay88","avatar":"https://static.tigerbbs.com/a2a8c91b2081859f5b526f88c16cc73a","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":875752330,"type":1,"supId":0,"prevId":0,"content":"ok","text":"ok","html":"ok"},{"id":6697199,"gmtCreate":1637705864890,"gmtModify":1637705865002,"authorId":3555067011639600,"author":{"id":3555067011639600,"authorId":3555067011639600,"name":"TraderJo98","avatar":"https://static.tigerbbs.com/4b2fb6c4a2935a517c3b7b2963f0308e","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":875752330,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":6697159,"gmtCreate":1637705626938,"gmtModify":1637705626966,"authorId":3576917742134919,"author":{"id":3576917742134919,"authorId":3576917742134919,"name":"T2C","avatar":"https://static.tigerbbs.com/18720cb4368721ede0a87e57a36d26df","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":875752330,"type":1,"supId":0,"prevId":0,"content":"Yes","text":"Yes","html":"Yes"}],"langContent":"CN"},{"id":875756310,"gmtCreate":1637705183288,"gmtModify":1637705183411,"author":{"id":"3583621807888930","authorId":"3583621807888930","name":"3eb0d2e3","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/875756310","repostId":1156228294,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6697126,"gmtCreate":1637705350454,"gmtModify":1637705350548,"authorId":3581539047362830,"author":{"id":3581539047362830,"authorId":3581539047362830,"name":"Sunny0809","avatar":"https://static.tigerbbs.com/3ffb7aab0292fd1f17dfb9f99bc5eb03","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":875756310,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":6697108,"gmtCreate":1637705191886,"gmtModify":1637705191914,"authorId":3583621807888930,"author":{"id":3583621807888930,"authorId":3583621807888930,"name":"3eb0d2e3","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":875756310,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":201,"commentSize":23,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.23.1","shortVersion":"4.23.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1156228294"}